J David Boyle II insider trades: Avi Biopharma (AVII) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where J reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 27, 2010 | AVII | ↑ Buy | 5,000 | $2.13 | $11K | Direct | Aug 27, 2010 (0d) |
| Mar 13, 2009 | AVII | ↑ Buy | 19,000 | $0.64 | $12K | Direct | Mar 13, 2009 (0d) |
| Aug 17, 2005 | XOMA | ↑ Buy | 5,000 | $1.44 | $7K | Direct | Aug 17, 2005 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About J David Boyle II's insider trades
J David Boyle II is CEO at Avi Biopharma (AVII). Since Aug 17, 2005, J has reported 3 open-market purchases worth $30K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (13 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AVII insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.